Phenobarbital placebos

Casey, J. E, Bennett, I. E, Lindley, C. J., Hollister, L. E., Gordon, M. H., Springer, N. N. 1960a, Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital, and placebo, Arch.Gen.Psychiatry, vol. 2, pp. 210-220. 

Clozapine has been used to treat benign essential tremor refractory to the usual drugs (propranolol, primidone, alprazolam, phenobarbital, and botulinum toxin) in a randomized, double-blind, crossover study in 15 patients with essential tremor (58). Responders with more than 50% improvement after a single dose of clozapine 12.5 mg, compared with placebo, subsequently received 39-50 mg unblinded for a mean of 16 months. Tremor was effectively reduced by a single dose of clozapine in 13 of 15 patients sedation was the only adverse effect reported. 

In a placebo-controlled study 15 healthy subjects were given phenobarbital 100 mg daily for 16 days with a single 100-mg dose of losartan. Phenobarbital slightly reduced the AUC of losartan and its active metabolite,... 

Doose DR, Walker SA, Plei er G, Lim P, Reife RA. Evaluation of phenobarbital and M imi-done/phenobarbital (primidone s active metabolite) plasma ccxicentmtions durii administration of add-on tcf iramate therapy in five multicenter, double-blind, placebo-caitrolled trials in outpatients with partial seizures Epilepsia (1995) 36 (Sui f>l 3), SI 58. 

Systematic reviews The major studies on the safety and tolerability of rufinamide were reviewed [157 ]. In placebo-controlled trials and pooled analyses, the most common adverse effects reported with rufinamide were somnolence and vomiting. Headache and pyrexia were also reported more frequently with rufinamide compared to placebo. In terms of drug-drug interactions, rufinamide may slightly increase the clearance of CBZ and lamotrigine and may slightly decrease the clearance of phenytoin and phenobarbital. VPA may significantly decrease the clearance of rufinamide. 

---